{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:26:31Z","timestamp":1761744391453},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/pcan.2016.31","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:22:45Z","timestamp":1470738165000},"page":"398-405","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer"],"prefix":"10.1038","volume":"19","author":[{"given":"R R","family":"McKay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P W","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-E","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"BFpcan201631_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3322\/canjclin.22.4.232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV . Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232\u2013240.","journal-title":"CA Cancer J Clin"},{"key":"BFpcan201631_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2015","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2015; 387: 1163\u20131177.","journal-title":"Lancet"},{"key":"BFpcan201631_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737\u2013746.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424\u2013433.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995\u20132005.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138\u2013148.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clgc.2011.06.006","volume":"9","author":"M Nakabayashi","year":"2011","unstructured":"Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME . Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer 2011; 9: 95\u2013103.","journal-title":"Clin Genitourin Cancer"},{"key":"BFpcan201631_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.eururo.2015.10.021","volume":"69","author":"J Bellmunt","year":"2015","unstructured":"Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF et al. Prior endocrine therapy impact on abiraterone acetate clinical efficacy in metastatic castration-resistant prostate cancer: post-hoc analysis of randomised phase 3 studies. Eur Urol 2015; 69: 924\u2013932.","journal-title":"Eur Urol"},{"key":"BFpcan201631_CR10","first-page":"5013","volume":"31","author":"KN Chi","year":"2013","unstructured":"Chi KN, Kheoh TS, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ et al. A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. ASCO Meeting Abstr 2013; 31: 5013.","journal-title":"ASCO Meeting Abstr"},{"key":"BFpcan201631_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/annonc\/mdv545","volume":"27","author":"K Fizazi","year":"2016","unstructured":"Fizazi K, Flaig TW, Stockle M, Scher HI, de Bono JS, Rathkopf DE et al. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol 2016; 27: 699\u2013705.","journal-title":"Ann Oncol"},{"key":"BFpcan201631_CR12","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.1158\/1078-0432.CCR-14-1595","volume":"20","author":"W Kim","year":"2014","unstructured":"Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V et al. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res 2014; 20: 6269\u20136276.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201631_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/annonc\/mdt581","volume":"25","author":"R Leibowitz-Amit","year":"2014","unstructured":"Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2014; 25: 657\u2013662.","journal-title":"Ann Oncol"},{"key":"BFpcan201631_CR14","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","volume":"24","author":"Y Loriot","year":"2013","unstructured":"Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807\u20131812.","journal-title":"Ann Oncol"},{"key":"BFpcan201631_CR15","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","volume":"51","author":"Y Loriot","year":"2015","unstructured":"Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L et al. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer 2015; 51: 1946\u20131952.","journal-title":"Eur J Cancer"},{"key":"BFpcan201631_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2014.03.020","volume":"66","author":"P Ravi","year":"2014","unstructured":"Ravi P, Mateo J, Lorente D, Zafeiriou Z, Altavilla A, Ferraldeschi R et al. External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. Eur Urol 2014; 66: 8\u201311.","journal-title":"Eur Urol"},{"key":"BFpcan201631_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3816\/CGC.2006.n.019","volume":"5","author":"WK Oh","year":"2006","unstructured":"Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006; 5: 61\u201366.","journal-title":"Clin Genitourin Cancer"},{"key":"BFpcan201631_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pros.23141","volume":"76","author":"R Nadal","year":"2016","unstructured":"Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR et al. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate 2016; 76: 512\u2013520.","journal-title":"Prostate"},{"key":"BFpcan201631_CR19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","volume":"21","author":"S Halabi","year":"2003","unstructured":"Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232\u20131237.","journal-title":"J Clin Oncol"},{"key":"BFpcan201631_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983\u2013992.","journal-title":"Lancet Oncol"},{"key":"BFpcan201631_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2014.08.025","volume":"67","author":"F Saad","year":"2015","unstructured":"Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M et al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol 2015; 67: 223\u2013230.","journal-title":"Eur Urol"},{"key":"BFpcan201631_CR22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"DC Danila","year":"2010","unstructured":"Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496\u20131501.","journal-title":"J Clin Oncol"},{"key":"BFpcan201631_CR23","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","volume":"24","author":"KL Noonan","year":"2013","unstructured":"Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN . Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802\u20131807.","journal-title":"Ann Oncol"},{"key":"BFpcan201631_CR24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/cncr.28518","volume":"120","author":"S Badrising","year":"2014","unstructured":"Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014; 120: 968\u2013975.","journal-title":"Cancer"},{"key":"BFpcan201631_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/pcan.2014.53","volume":"18","author":"HH Cheng","year":"2015","unstructured":"Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel. Prostate Cancer Prostatic Dis 2015; 18: 122\u2013127.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201631_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/pros.22874","volume":"74","author":"R Nadal","year":"2014","unstructured":"Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ et al. Clinical activity of enzalutamide in Docetaxel-naive and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 2014; 74: 1560\u20131568.","journal-title":"Prostate"},{"key":"BFpcan201631_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","volume":"65","author":"AJ Schrader","year":"2014","unstructured":"Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30\u201336.","journal-title":"Eur Urol"},{"key":"BFpcan201631_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 2015; 41: 884\u2013892.","journal-title":"Cancer Treat Rev"},{"key":"BFpcan201631_CR29","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943\u20132947.","journal-title":"Ann Oncol"},{"key":"BFpcan201631_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","volume":"66","author":"MT Schweizer","year":"2014","unstructured":"Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 66: 646\u2013652.","journal-title":"Eur Urol"},{"key":"BFpcan201631_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/1078-0432.CCR-14-1358","volume":"21","author":"R de Leeuw","year":"2015","unstructured":"de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res 2015; 21: 795\u2013807.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201631_CR32","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","volume":"31","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 2013; 31: 2791\u20132798.","journal-title":"J Clin Oncol"},{"key":"BFpcan201631_CR33","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028\u20131038.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215\u20131228.","journal-title":"Cell"},{"key":"BFpcan201631_CR35","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1021\/jm501239f","volume":"58","author":"VC Njar","year":"2015","unstructured":"Njar VC, Brodie AM . Discovery and development of Galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer. J Med Chem 2015; 58: 2077\u20132087.","journal-title":"J Med Chem"},{"key":"BFpcan201631_CR36","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697\u20131708.","journal-title":"N Engl J Med"},{"key":"BFpcan201631_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/cncr.23304","volume":"112","author":"RW Ross","year":"2008","unstructured":"Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112: 1247\u20131253.","journal-title":"Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201631","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:09:25Z","timestamp":1648674565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFpcan201631"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.31","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]},"assertion":[{"value":"7 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M-ET receives research funding and advisory board honorarium from Janssen. PWK is a paid advisor to Janssen. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}